Aberdeen Group plc reduced its position in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 61.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 750,697 shares of the medical research company’s stock after selling 1,180,828 shares during the quarter. Aberdeen Group plc owned 0.58% of NeoGenomics worth $13,783,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. First Light Asset Management LLC raised its position in shares of NeoGenomics by 26.2% in the second quarter. First Light Asset Management LLC now owns 12,279,523 shares of the medical research company’s stock valued at $179,158,000 after purchasing an additional 2,549,545 shares during the period. First Trust Advisors LP acquired a new stake in shares of NeoGenomics during the 1st quarter worth about $45,725,000. Dimensional Fund Advisors LP raised its position in NeoGenomics by 9.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,674,335 shares of the medical research company’s stock worth $19,842,000 after purchasing an additional 225,588 shares during the last quarter. American Capital Management Inc. acquired a new position in shares of NeoGenomics in the 2nd quarter valued at $32,648,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of NeoGenomics in the 2nd quarter valued at approximately $10,744,000. 98.50% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research analysts have commented on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $21.00 price objective on shares of NeoGenomics in a report on Thursday, October 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a report on Monday, October 12th. BTIG Research reissued a “buy” rating and set a $28.00 price target on shares of NeoGenomics in a research report on Thursday, October 29th. Piper Sandler reiterated an “overweight” rating on shares of NeoGenomics in a research report on Wednesday, October 7th. Finally, Zacks Research cut shares of NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Eight research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.88.
NeoGenomics Trading Up 0.3%
Shares of NASDAQ:NEO opened at $15.29 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 3.53 and a quick ratio of 3.31. NeoGenomics, Inc. has a 52-week low of $7.07 and a 52-week high of $20.15. The business’s 50 day moving average is $17.42 and its 200 day moving average is $13.07.
NeoGenomics (NASDAQ:NEO – Get Free Report) last posted its earnings results on Wednesday, October 28th. The medical research company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. NeoGenomics had a negative net margin of 4.10% and a negative return on equity of 0.99%. The firm had revenue of $209.25 million during the quarter, compared to analyst estimates of $206.70 million. During the same period in the previous year, the firm earned $0.03 EPS. The business’s quarterly revenue was up 11.3% on a year-over-year basis. Sell-side analysts predict that NeoGenomics, Inc. will post -0.06 EPS for the current fiscal year.
NeoGenomics Company Profile
NeoGenomics is a cancer-focused diagnostics company that provides laboratory testing and related services to physicians, hospitals, pharmaceutical companies and other healthcare organizations. Its clinical testing helps support the diagnosis and treatment of cancer. The company offers a range of oncology tests, including molecular, cytogenetic, pathology and flow cytometry services. Its capabilities also include next-generation sequencing and liquid biopsy testing, which can help clinicians assess tumor characteristics and inform treatment decisions.
Read More
- Five stocks we like better than NeoGenomics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.
